Oligo Synthesis

Oligo synthesis

DNA RNA End-to-End Oligonucleotide
CDMO & CRO Service

DNA

All oligos provided by Bioneer are applied to the AccuOligo® system, and all oligos are produced in a clean room and supplied to customers in a DNase, RNase, and DNA free state. Generally, supplied oligos go through synthesis, purification, QC, and dispensing processes, are dried, and are then delivered to customers. In the case of conventional synthesis services, there is a chance that dried oligos may fall during their delivery from shaking and impacts.

If the containers are opened during the delivery, parts of oligos may fall out, leading to yield loss. This may be much more severe when ordered in plates as cross-contaminations may occur. AccuOligo® technology allows the synthesized oligonucleotides to stick at the bottom of the tube even under intense vibrations. (Dried oligonucleotide composition of the new patent application’ Patent 2006 Registration Number 10-0777249)

Order

Preventing dislodging and loss of oligos during production, packaging, and shipping

Containing “Leak Inhibitors” not affecting protocols such as PCR, Sequencing, Enzyme cutting, etc.

Overcomes the phenomenon of small amounts of Oligo adhering to the lid

Prevent contamination between each well in the plate

Order

Thorough quality control

A total of 7 MALDI-TOF spectrometers are used to conduct QC inspection.
High-quality oligo

Supply of nuclease-free, DNA-free oligo by synthesizing in a clean room and eliminating truncated failures including n-1 mer with our proprietary Bio-RP high-purity purification system.
Exact concentration

To deliver with exact concentration, Bioneer use automatic dosing dispenser and Accuoligo® technology, to prevent the loss of oligo during transportation and opening.
Automated production

By establishing the world's first automated production line process, the entire process from ordering to synthesis, QC, and packaging is automated and produced using the ‘Computer Aided Manufacturing (CAM) system.’
Mass production capacity

Able to produce maximum of 30,500 synthetic genes per day, and large-scale synthesis in mg to kg units is possible.

RNA

Bioneer siRNAs are manufactured in an RNase-free clean room and have proven to be highly efficient and stable after undergoing a strict QC process. Using the highly efficient Turbo si-Designer, 132,000 predesigned siRNAs have been designed and prepared for 44,000 target genes in humans, mice, and rats, with over 250 different modifications.

Turbo si-Designer

In collaboration with NGIC, we've created Turbo si-Designer, an algorithm for designing siRNAs. Our Genome-wide siRNA database offers highly efficient knockdown options.

The Bioneer's Guarantee

Guarantee Purchase three siRNAs for the same gene: We guarantee 80% or higher mRNA knockdown efficiency for at least two out of three. If not met, we'll provide additional siRNAs free of charge until the desired efficiency is achieved.

AccuTarget™ Genome-Wide Predesigned siRNA

Maximizes siRNA knockdown efficiency while minimizing off-target effects.

Order

Single strand RNA

Custom RNA Synthesis is a service that synthesizes RNA sequences requested by customers, and over 250 different modifications are available.

Order

Double strand RNA

Custom siRNA Synthesis is a service that synthesizes siRNA sequences requested by customers, and over 250 different modifications are available.

Order

AccuTarget ™ Human miRNA mimics & inhibitors

AccuTarget ™ human miRNA is provided by synthesizing the sequence information of miRBase Ver.22.

Order

AccuTarget ™ miRNA Controls

Verified highly efficient target gene KD effect AccuTarget ™ PC siRNA (Human GAPDH, GFP, Luciferase)

Order

AccuTarget ™ siRNA Controls

Verified highly efficient target gene KD effect AccuTarget ™ PC siRNA (Human GAPDH, GFP, Luciferase) Products with low homology to the target geneAccuTarget ™ NC siRNA (for Human, Mouse, Rat)

Order

AccuTarget™ qPCR Primer Library

Real-time PCR primers for 11,154 human predesigned siRNAs with proven amplification efficiency.

Order

Oligonucleotide CDMO & CRO Service

Step 01

Oligonucleotide Candidate Discovery & Screening

We offer comprehensive, MIQE guideline-compliant RNAi high-throughput screening services to identify and prioritize potent oligonucleotide sequences at the early stages of drug discovery.

Key features include:

High-throughput screening using 384-well and 96-well automated platforms
Sequence optimization to enhance efficacy and minimize off-target effects
Safety assessment through inflammatory cytokine response and cytotoxicity assays

These discovery-focused services accelerate lead candidate identification and support a smooth transition into the manufacturing phase.

Step 02

Oligonucleotide Manufacturing (CDMO)

We provide therapeutic oligonucleotide manufacturing services suitable for preclinical and clinical development stages, supported by robust and reliable CDMO capabilities.

Our services include:

Process development, optimization, and analytical support for clinical development
Early-stage CMC data generation
Process development and scale-up synthesis
Purification and quality control (QC)
Support for diverse oligonucleotide formats

Through a structured and systematic CDMO framework, we ensure a stable supply of high-quality materials while offering flexible manufacturing solutions tailored to each stage of development. This enables seamless progression from early development to clinical manufacturing.

Step 03

Integrated In-vivo & Histopathology Solutions

BIONEER integrates In-vivo CRO services with histopathological analysis into a single platform, providing an optimized evaluation solution that enhances the translational potential of drug candidates.

Our integrated services include:

In-vivo pharmacology and efficacy studies: Systematic validation of mechanism of action (MOA) and therapeutic efficacy through refined disease modeling
Toxicity and safety evaluation: Early identification of potential risks to ensure project stability during development
Histopathology and biomarker analysis: Precise tissue-level analysis to clearly elucidate biological responses to drug candidates

Beyond simple data delivery, we provide integrated reports combining in-vivo responses with histopathological insights, enabling faster and more accurate Go/No-Go decision-making.

Service Order Information

Please download and complete the service order form, then send it to: info@sirnagen.com

Download Order Form